Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million
  • BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock
  • Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share
  • The placement is expected to close on June 7
  • BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer
  • BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET

BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million.

BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share.

This private placement is expected to close on June 7, 2021.

BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer.

BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET.

More From The Market Herald
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.